Skip to content

MOH

Molina Healthcare, Inc.

NYSE · Healthcare · Medical - Healthcare Plans · US

$200.80
−1.04%
Ask drillr

Research · Sep 3, 2026

[MOH] Molina Healthcare Thesis 2026: Medicaid Contract Wins Anchor Managed Care Cycle

Molina Healthcare Inc. FY2025 revenue ~$40-42B (+5-7%) with adj. EPS ~$22.00-23.00 reflecting continued Medicaid managed care contract wins + selected Medicare growth + selected Marketplace expansion partially offset by selected redetermination cycle volume normalization (post-COVID Medicaid eligibility redetermination compressed Medicaid membership FY2023-2025; Molina lost ~500-700K members during redetermination). Large US managed care organization specializing in Medicaid + Medicare + Marketplace plans; founded 1980 by Dr. C. David Molina in Long Beach California. Headquartered in Long Beach California. 3 segments: Medicaid ~70% ($28-30B — ~22 state Medicaid managed care contracts; ~3.5-4M+ members; major states include California + Texas + Washington + Ohio + Mississippi + Idaho + selected) + Medicare ~20% ($8-9B — Medicare Advantage + Special Needs Plans D-SNPs for dual-eligible; ~1M+ members) + Marketplace ~10% ($4-4.5B — ACA Marketplace plans; ~500-700K members). ~5.5M+ total members served (vs ~5M+ FY2022 pre-redetermination). CEO Joseph Zubretsky since November 2017 (succeeded Molina family-led leadership amid 2017 family departures + selected board-led operational reset; Zubretsky ex-The Hanover Insurance Group CEO 2013-2016 + ex-Aetna SVP 2007-2013; ~25-year insurance/managed care executive career). Zubretsky tenure executed transformational margin recovery + selected operational discipline + aggressive Medicaid RFP win track record 2018-2024 + selected Medicare Advantage growth + selected redetermination cycle navigation. Capital return: no dividend + buybacks $500M-1B (~1-2%/yr share count reduction); net debt minimal (selected MCO model with reserves); Ba2/BB+ investment grade. FY2026 thesis: Medicaid contract wins + Medicare Advantage growth + operational discipline + capital return. Risks: Medicaid reimbursement, contract retention, redetermination cycle.

Research · Apr 9, 2026

Medicare Advantage 2026 Rate Hike: UNH and HUM Lead Margin Winners — Ranked

The April 7, 2026, Medicare Advantage rate decision sparked gains for UNH and HUM, signaling margin relief for exposed insurers. UNH leads with balanced exposure and scale, followed by HUM's pure-play bet and CI's value. Rankings prioritize MA leverage, growth, and valuations amid stabilizing reimbursements.